BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2023 Earnings Call Transcript
Operator: Good morning, and welcome to the BioXcel Therapeutics First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Bioxcel Therapeutics Inc. (BTAI)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value (x$1000) | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Adage Capital Management Phill Gross And Robert Atchinson | 2,081,979 | $38,849,728 | +138% | 0.08% |
| 2. | Driehaus Capital Richard Driehaus | 388,765 | $7,254,355 | -24% | 0.1% |
| 3. | Ikarian Capital Neil Shahrestani | 133,014 | $2,482,041 | -47% | 0.56% |
| 4. | Citadel Investment Group Ken Griffin | 84,432 | $1,575,501 | +82% | 0% |
| 5. | 71,200 | $1,328,592 | 0.3% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $11.00 | 2,000 | Officer, Director | 2,000 | 2018-03-12 | Filing | |
| $9.34 | 1,554 | Director | 168,320 | 2019-08-23 | Filing | |
| $8.83 | 6,646 | Director | 166,766 | 2019-08-22 | Filing | |
| $8.42 | 1,800 | Director | 160,120 | 2019-08-21 | Filing | |
| $8.89 | 974 | Officer, Director | 9,957 | 2019-08-16 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $25.79 | 6,500 | Officer, Director | 37,294 | 2023-05-22 | Filing | |
| $27.17 | 5,000 | Officer | 1,500 | 2023-05-15 | Filing | |
| $27.32 | 1,785 | Officer | 4,350 | 2023-05-15 | Filing | |
| $17.32 | 60,000 | Large Shareholder, Director | 0 | 2023-04-06 | Filing | |
| $20.15 | 900 | Officer, Director | 15,894 | 2023-03-21 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value (x$1000) | % Port |
|---|---|---|---|---|
| 1. | 4,276,693 | $79,803,091 | 0% | |
| 2. | 1,760,683 | $32,854,345 | 0% | |
| 3. | 1,370,688 | $25,577,038 | 0% | |
| 4. | 1,334,606 | $24,903,748 | 0% | |
| 5. | 1,063,974 | $19,853,756 | 0% |
News See All
BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q4 2022 Earnings Call Transcript
Operator: Good morning, and welcome to the BioXcel Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode.
Hedge Fund and Insider Trading News: Toscafund Management, Oaktree Capital Management, Worm Capital, BlackRock, Inc. (BLK), and More
MADRID (Reuters) - Fund manager Reade Griffith bought a minority stake in Spanish broadcaster Mediaset Espana after its parent company MediaForEurope launched a public takeover offer, a filing to the ...
Hedge Funds Are Dumping BioXcel Therapeutics, Inc. (BTAI)
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Is BTAI A Good Stock To Buy Now?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious...
Hedge Funds Are Warming Up To BioXcel Therapeutics, Inc. (BTAI)
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Hedge Funds Have Never Been This Bullish On BioXcel Therapeutics, Inc. (BTAI)
Is BioXcel Therapeutics, Inc. (NASDAQ:BTAI) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research.
Billionaire Hedge Funds
